MD
Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of telisotuzumab vedotin, an antibody-drug conjugate, for NSCLC with high c-MET expression. Dr. Mor Moskovitz and Dr. Jonathan Goldman joined the conversation to help review the data and offer perspective on this new agent.